DeepMed Research

ROCHESTER GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1847-01-01

Employees: -

Market Cap: -

Website: http://www.rochesterregional.org/locations/hospitals/rochester-general-hospital

Clinical Trials

Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

Phase 2

Recruiting

Conditions: COPD Exacerbation Acute

Interventions: Biological: CUVITRU - Ig subcutaneous human 20%
Other: Standard Medical Therapy

First Posted Date: 2023-03-13

Last Posted Date: 2023-06-15

Lead Sponsor: Rochester General Hospital

Target Recruit Count: 40

Registration Number: NCT05764993

Locations: 🇺🇸
Rochester Regional Health Ctr for Clinical Research - Alexander Park, Rochester, New York, United States
🇺🇸
Rochester Regional Health - Ctr for Clinical Research - Linden Oaks, Rochester, New York, United States
🇺🇸
Rochester Regional Health - Ctr for Clinical Research - Greece, Rochester, New York, United States

Dynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens

Not Applicable

Active, not recruiting

Conditions: Acute Otitis Media

Interventions: Procedure: Tympanocentesis
Other: Nasal Phalangeal Swab and Wash
Other: Blood Draw

First Posted Date: 2021-06-30

Last Posted Date: 2023-11-22

Lead Sponsor: Rochester General Hospital

Target Recruit Count: 320

Registration Number: NCT04946084

Locations: 🇺🇸
Rochester General Hospital, Rochester, New York, United States

Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

Phase 2

Completed

Conditions: Secondary Immune Deficiency Disorder

Interventions: Drug: Hizentra

First Posted Date: 2018-11-05

Last Posted Date: 2020-08-26

Lead Sponsor: Rochester General Hospital

Target Recruit Count: 20

Registration Number: NCT03730129

Locations: 🇺🇸
Allergy, Immunology, Rheumatology at Rochester Regional Health, Rochester, New York, United States

Dupilumab for Aspirin-exacerbated Respiratory Disease

Phase 2

Completed

Conditions: Aspirin-exacerbated Respiratory Disease

Interventions: Drug: Dupilumab

First Posted Date: 2018-07-23

Last Posted Date: 2020-08-26

Lead Sponsor: Rochester General Hospital

Target Recruit Count: 11

Registration Number: NCT03595488

Locations: 🇺🇸
Rochester Regional Health - Allergy/Immunology, Rochester, New York, United States

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

Phase 2

Completed

Conditions: Secondary Immune Deficiency

Interventions: Drug: 20% subcutaneous immunoglobulin

First Posted Date: 2017-07-07

Last Posted Date: 2021-04-19

Lead Sponsor: Rochester General Hospital

Target Recruit Count: 16

Registration Number: NCT03211065

Locations: 🇺🇸
Allergy and Immunology, 222 Alexander Street, Rochester, New York, United States

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

Phase 4

Terminated

Conditions: Clostridium Difficile Infection

Interventions: Drug: Oral Vancomycin
Drug: Placebo

First Posted Date: 2017-06-27

Last Posted Date: 2021-04-26

Lead Sponsor: Rochester General Hospital

Target Recruit Count: 65

Registration Number: NCT03200093

Locations: 🇺🇸
Rochester General Hospital, Rochester, New York, United States

Evaluate Pathogens and Immunity to Acute Otitis Media in Healthy Children.

Active, not recruiting

Conditions: Nasopharyngeal Colonization and Acute Otitis Media

Interventions: Other: procedures

First Posted Date: 2015-10-29

Last Posted Date: 2023-11-22

Lead Sponsor: Rochester General Hospital

Target Recruit Count: 1320

Registration Number: NCT02591563

Locations: 🇺🇸
Rochester General Hospital, Rochester, New York, United States

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

Phase 2

Terminated

Conditions: Cutaneous T-cell Lymphoma
Mycosis Fungoides
Sezary Syndrome

Interventions: Drug: Doxycycline monohydrate

First Posted Date: 2015-01-19

Last Posted Date: 2021-04-27

Lead Sponsor: Rochester General Hospital

Target Recruit Count: 1

Registration Number: NCT02341209

Locations: 🇺🇸
Rochester General Hospital, Rochester, New York, United States

Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

Not Applicable

Withdrawn

Conditions: Mycosis Fungoides

Interventions: Drug: 3.75% Imiquimod Cream
Drug: 0.1% Fluocinonide Cream

First Posted Date: 2014-11-26

Last Posted Date: 2021-04-27

Lead Sponsor: Rochester General Hospital

Registration Number: NCT02301494

Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium

Phase 4

Withdrawn

Conditions: Delirium
Agitation

Interventions: Drug: Placebo
Drug: Trazodone
Drug: Risperidone

First Posted Date: 2014-04-21

Last Posted Date: 2019-09-10

Lead Sponsor: Rochester General Hospital

Registration Number: NCT02118688

Locations: 🇺🇸
Rochester General Hospital, Rochester, New York, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy